BIOMAT Database Logo BIOMAT Database Logo

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds. 1997

F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Department of Chemistry, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.

Novel tricyclic Ras farnesyl-protein transferase (FPT) inhibitors are described. A comprehensive structure-activity relationship (SAR) study of compounds arising from substitution at the 3-position of the tricyclic pyridine ring system has been explored. In the case of halogens, the chloro, bromo, and iodo analogues 19, 22, and 28 were found to be equipotent. However, the fluoro analogue 17 was an order of magnitude less active. Whereas a small alkyl substituent such as a methyl group resulted in a very potent FPT inhibitor (SCH 56580), introduction of bulky substituents such as tert-butyl, compound 33, or a phenyl group, compound 29, resulted in inactive FPT inhibitors. Polar groups at the 3-position such as amino 5, alkylamino 6, and hydroxyl 12 were less active. Whereas compound SCH 44342 did not show appreciable in vivo antitumor activity, the 3-bromo-substituted pyridyl N-oxide amide analogue 38 was a potent FPT inhibitor that reduced tumor growth by 81% when administered q.i.d. at 50 mpk and 52% at 10 mpk. These compounds are nonpeptidic and do not contain sulfhydryl groups. They selectively inhibit FPT and not geranylgeranyl-protein transferase-1 (GGPT-1). They also inhibit H-Ras processing in COS monkey kidney cells and soft agar growth of Ras-transformed cells.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010880 Piperidines A family of hexahydropyridines.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections

Related Publications

F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.
February 2002, Bioorganic & medicinal chemistry letters,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
September 2010, Indian journal of pharmaceutical sciences,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
March 1998, Journal of medicinal chemistry,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.
September 1999, Bioorganic & medicinal chemistry,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
N-substituted 11-(4-piperidylene)-5,6-dihydro-11H-benzo-[5,6]cyclohepta [1,2-b]pyridines. Antihistamines with no sedating liability.
September 1986, Arzneimittel-Forschung,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.
July 1999, Bioorganic & medicinal chemistry letters,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.
January 1991, Journal of medicinal chemistry,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
August 2002, Journal of medicinal chemistry,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Synthesis and pharmacological properties of some derivatives of 5H-benzo (4,5) cyclohepta (1,2-b) pyridine nd of 11H-benzo (5,6) cyclohepta (1,2-c) pyridine. 3.
January 1972, Arzneimittel-Forschung,
F G Njoroge, and B Vibulbhan, and D F Rane, and W R Bishop, and J Petrin, and R Patton, and M S Bryant, and K J Chen, and A A Nomeir, and C C Lin, and M Liu, and I King, and J Chen, and S Lee, and B Yaremko, and J Dell, and P Lipari, and M Malkowski, and Z Li, and J Catino, and R J Doll, and V Girijavallabhan, and A K Ganguly
Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
August 2005, Molecular pharmacology,
Copied contents to your clipboard!